id	sid	tid	token	lemma	pos
work_kipbknbmlvekxopym6tsxywxe4	1	1	the	the	DT
work_kipbknbmlvekxopym6tsxywxe4	1	2	distillery	distillery	NN
work_kipbknbmlvekxopym6tsxywxe4	1	3	SciBX	scibx	NN
work_kipbknbmlvekxopym6tsxywxe4	1	4	:	:	:
work_kipbknbmlvekxopym6tsxywxe4	1	5	Science	Science	NNP
work_kipbknbmlvekxopym6tsxywxe4	1	6	–	–	:
work_kipbknbmlvekxopym6tsxywxe4	1	7	Business	Business	NNP
work_kipbknbmlvekxopym6tsxywxe4	1	8	eXchange	eXchange	NNP
work_kipbknbmlvekxopym6tsxywxe4	1	9	Copyright	Copyright	NNP
work_kipbknbmlvekxopym6tsxywxe4	1	10	©	©	NNP
work_kipbknbmlvekxopym6tsxywxe4	1	11	2008	2008	CD
work_kipbknbmlvekxopym6tsxywxe4	1	12	Nature	Nature	NNP
work_kipbknbmlvekxopym6tsxywxe4	1	13	Publishing	Publishing	NNP
work_kipbknbmlvekxopym6tsxywxe4	1	14	Group	Group	NNP
work_kipbknbmlvekxopym6tsxywxe4	1	15	�	�	NNP
work_kipbknbmlvekxopym6tsxywxe4	1	16	This	this	DT
work_kipbknbmlvekxopym6tsxywxe4	1	17	week	week	NN
work_kipbknbmlvekxopym6tsxywxe4	1	18	in	in	IN
work_kipbknbmlvekxopym6tsxywxe4	1	19	therapeutics	therapeutic	NNS
work_kipbknbmlvekxopym6tsxywxe4	1	20	Indication	Indication	NNP
work_kipbknbmlvekxopym6tsxywxe4	1	21	Target	Target	NNP
work_kipbknbmlvekxopym6tsxywxe4	1	22	/	/	SYM
work_kipbknbmlvekxopym6tsxywxe4	1	23	marker/	marker/	NNP
work_kipbknbmlvekxopym6tsxywxe4	1	24	pathway	pathway	NN
work_kipbknbmlvekxopym6tsxywxe4	1	25	Summary	Summary	NNP
work_kipbknbmlvekxopym6tsxywxe4	1	26	Licensing	Licensing	NNP
work_kipbknbmlvekxopym6tsxywxe4	1	27	status	status	NN
work_kipbknbmlvekxopym6tsxywxe4	1	28	Publication	publication	NN
work_kipbknbmlvekxopym6tsxywxe4	1	29	and	and	CC
work_kipbknbmlvekxopym6tsxywxe4	1	30	contact	contact	NN
work_kipbknbmlvekxopym6tsxywxe4	1	31	information	information	NN
work_kipbknbmlvekxopym6tsxywxe4	1	32	Cancer	Cancer	NNP
work_kipbknbmlvekxopym6tsxywxe4	1	33	Colon	Colon	NNP
work_kipbknbmlvekxopym6tsxywxe4	1	34	cancer	cancer	NN
work_kipbknbmlvekxopym6tsxywxe4	1	35	Guanylyl	Guanylyl	NNP
work_kipbknbmlvekxopym6tsxywxe4	1	36	cyclase	cyclase	NN
work_kipbknbmlvekxopym6tsxywxe4	1	37	2C	2c	NN
work_kipbknbmlvekxopym6tsxywxe4	1	38	(	(	-LRB-
work_kipbknbmlvekxopym6tsxywxe4	1	39	heat	heat	NN
work_kipbknbmlvekxopym6tsxywxe4	1	40	-	-	HYPH
work_kipbknbmlvekxopym6tsxywxe4	1	41	stable	stable	JJ
work_kipbknbmlvekxopym6tsxywxe4	1	42	enterotoxin	enterotoxin	NN
work_kipbknbmlvekxopym6tsxywxe4	1	43	receptor	receptor	NN
work_kipbknbmlvekxopym6tsxywxe4	1	44	;	;	:
work_kipbknbmlvekxopym6tsxywxe4	1	45	GUCY2C	gucy2c	LS
work_kipbknbmlvekxopym6tsxywxe4	1	46	)	)	-RRB-
work_kipbknbmlvekxopym6tsxywxe4	1	47	Studies	study	NNS
work_kipbknbmlvekxopym6tsxywxe4	1	48	in	in	IN
work_kipbknbmlvekxopym6tsxywxe4	1	49	mice	mouse	NNS
work_kipbknbmlvekxopym6tsxywxe4	1	50	suggest	suggest	VBP
work_kipbknbmlvekxopym6tsxywxe4	1	51	that	that	IN
work_kipbknbmlvekxopym6tsxywxe4	1	52	immunization	immunization	NN
work_kipbknbmlvekxopym6tsxywxe4	1	53	with	with	IN
work_kipbknbmlvekxopym6tsxywxe4	1	54	GUCY2C	GUCY2C	NNP
work_kipbknbmlvekxopym6tsxywxe4	1	55	could	could	MD
work_kipbknbmlvekxopym6tsxywxe4	1	56	help	help	VB
work_kipbknbmlvekxopym6tsxywxe4	1	57	treat	treat	VB
work_kipbknbmlvekxopym6tsxywxe4	1	58	or	or	CC
work_kipbknbmlvekxopym6tsxywxe4	1	59	prevent	prevent	VB
work_kipbknbmlvekxopym6tsxywxe4	1	60	metastatic	metastatic	JJ
work_kipbknbmlvekxopym6tsxywxe4	1	61	colon	colon	NN
work_kipbknbmlvekxopym6tsxywxe4	1	62	cancer	cancer	NN
work_kipbknbmlvekxopym6tsxywxe4	1	63	.	.	.
work_kipbknbmlvekxopym6tsxywxe4	2	1	In	in	IN
work_kipbknbmlvekxopym6tsxywxe4	2	2	healthy	healthy	JJ
work_kipbknbmlvekxopym6tsxywxe4	2	3	mice	mouse	NNS
work_kipbknbmlvekxopym6tsxywxe4	2	4	,	,	,
work_kipbknbmlvekxopym6tsxywxe4	2	5	immunization	immunization	NN
work_kipbknbmlvekxopym6tsxywxe4	2	6	with	with	IN
work_kipbknbmlvekxopym6tsxywxe4	2	7	GUCY2C	GUCY2C	NNP
work_kipbknbmlvekxopym6tsxywxe4	2	8	-	-	HYPH
work_kipbknbmlvekxopym6tsxywxe4	2	9	expressing	express	VBG
work_kipbknbmlvekxopym6tsxywxe4	2	10	viral	viral	JJ
work_kipbknbmlvekxopym6tsxywxe4	2	11	vectors	vector	NNS
work_kipbknbmlvekxopym6tsxywxe4	2	12	before	before	IN
work_kipbknbmlvekxopym6tsxywxe4	2	13	challenge	challenge	NN
work_kipbknbmlvekxopym6tsxywxe4	2	14	with	with	IN
work_kipbknbmlvekxopym6tsxywxe4	2	15	GUCY2C	GUCY2C	NNP
work_kipbknbmlvekxopym6tsxywxe4	2	16	-	-	HYPH
work_kipbknbmlvekxopym6tsxywxe4	2	17	expressing	express	VBG
work_kipbknbmlvekxopym6tsxywxe4	2	18	mouse	mouse	NN
work_kipbknbmlvekxopym6tsxywxe4	2	19	colon	colon	NN
work_kipbknbmlvekxopym6tsxywxe4	2	20	cancer	cancer	NN
work_kipbknbmlvekxopym6tsxywxe4	2	21	cells	cell	NNS
work_kipbknbmlvekxopym6tsxywxe4	2	22	minimized	minimize	VBD
work_kipbknbmlvekxopym6tsxywxe4	2	23	metastasis	metastasis	NN
work_kipbknbmlvekxopym6tsxywxe4	2	24	to	to	IN
work_kipbknbmlvekxopym6tsxywxe4	2	25	the	the	DT
work_kipbknbmlvekxopym6tsxywxe4	2	26	liver	liver	NN
work_kipbknbmlvekxopym6tsxywxe4	2	27	and	and	CC
work_kipbknbmlvekxopym6tsxywxe4	2	28	lungs	lung	NNS
work_kipbknbmlvekxopym6tsxywxe4	2	29	compared	compare	VBN
work_kipbknbmlvekxopym6tsxywxe4	2	30	with	with	IN
work_kipbknbmlvekxopym6tsxywxe4	2	31	that	that	DT
work_kipbknbmlvekxopym6tsxywxe4	2	32	seen	see	VBN
work_kipbknbmlvekxopym6tsxywxe4	2	33	in	in	IN
work_kipbknbmlvekxopym6tsxywxe4	2	34	mock	mock	NN
work_kipbknbmlvekxopym6tsxywxe4	2	35	-	-	HYPH
work_kipbknbmlvekxopym6tsxywxe4	2	36	treated	treat	VBN
work_kipbknbmlvekxopym6tsxywxe4	2	37	control	control	NN
work_kipbknbmlvekxopym6tsxywxe4	2	38	mice	mouse	NNS
work_kipbknbmlvekxopym6tsxywxe4	2	39	(	(	-LRB-
work_kipbknbmlvekxopym6tsxywxe4	2	40	p=0.008	p=0.008	NNP
work_kipbknbmlvekxopym6tsxywxe4	2	41	and	and	CC
work_kipbknbmlvekxopym6tsxywxe4	2	42	p<0.001	p<0.001	CD
work_kipbknbmlvekxopym6tsxywxe4	2	43	,	,	,
work_kipbknbmlvekxopym6tsxywxe4	2	44	respectively	respectively	RB
work_kipbknbmlvekxopym6tsxywxe4	2	45	)	)	-RRB-
work_kipbknbmlvekxopym6tsxywxe4	2	46	.	.	.
work_kipbknbmlvekxopym6tsxywxe4	3	1	In	in	IN
work_kipbknbmlvekxopym6tsxywxe4	3	2	mice	mouse	NNS
work_kipbknbmlvekxopym6tsxywxe4	3	3	with	with	IN
work_kipbknbmlvekxopym6tsxywxe4	3	4	established	establish	VBN
work_kipbknbmlvekxopym6tsxywxe4	3	5	metastases	metastasis	NNS
work_kipbknbmlvekxopym6tsxywxe4	3	6	,	,	,
work_kipbknbmlvekxopym6tsxywxe4	3	7	median	median	JJ
work_kipbknbmlvekxopym6tsxywxe4	3	8	survival	survival	NN
work_kipbknbmlvekxopym6tsxywxe4	3	9	was	be	VBD
work_kipbknbmlvekxopym6tsxywxe4	3	10	38	38	CD
work_kipbknbmlvekxopym6tsxywxe4	3	11	days	day	NNS
work_kipbknbmlvekxopym6tsxywxe4	3	12	for	for	IN
work_kipbknbmlvekxopym6tsxywxe4	3	13	immunized	immunized	JJ
work_kipbknbmlvekxopym6tsxywxe4	3	14	mice	mouse	NNS
work_kipbknbmlvekxopym6tsxywxe4	3	15	compared	compare	VBN
work_kipbknbmlvekxopym6tsxywxe4	3	16	with	with	IN
work_kipbknbmlvekxopym6tsxywxe4	3	17	29	29	CD
work_kipbknbmlvekxopym6tsxywxe4	3	18	days	day	NNS
work_kipbknbmlvekxopym6tsxywxe4	3	19	for	for	IN
work_kipbknbmlvekxopym6tsxywxe4	3	20	untreated	untreated	JJ
work_kipbknbmlvekxopym6tsxywxe4	3	21	mice	mouse	NNS
work_kipbknbmlvekxopym6tsxywxe4	3	22	(	(	-LRB-
work_kipbknbmlvekxopym6tsxywxe4	3	23	p=0.024	p=0.024	NNP
work_kipbknbmlvekxopym6tsxywxe4	3	24	)	)	-RRB-
work_kipbknbmlvekxopym6tsxywxe4	3	25	.	.	.
work_kipbknbmlvekxopym6tsxywxe4	4	1	The	the	DT
work_kipbknbmlvekxopym6tsxywxe4	4	2	antitumor	antitumor	NN
work_kipbknbmlvekxopym6tsxywxe4	4	3	and	and	CC
work_kipbknbmlvekxopym6tsxywxe4	4	4	prosurvival	prosurvival	JJ
work_kipbknbmlvekxopym6tsxywxe4	4	5	effects	effect	NNS
work_kipbknbmlvekxopym6tsxywxe4	4	6	occurred	occur	VBD
work_kipbknbmlvekxopym6tsxywxe4	4	7	without	without	IN
work_kipbknbmlvekxopym6tsxywxe4	4	8	autoimmune	autoimmune	JJ
work_kipbknbmlvekxopym6tsxywxe4	4	9	reactions	reaction	NNS
work_kipbknbmlvekxopym6tsxywxe4	4	10	.	.	.
work_kipbknbmlvekxopym6tsxywxe4	5	1	Completion	completion	NN
work_kipbknbmlvekxopym6tsxywxe4	5	2	of	of	IN
work_kipbknbmlvekxopym6tsxywxe4	5	3	safety	safety	NN
work_kipbknbmlvekxopym6tsxywxe4	5	4	and	and	CC
work_kipbknbmlvekxopym6tsxywxe4	5	5	efficacy	efficacy	NN
work_kipbknbmlvekxopym6tsxywxe4	5	6	studies	study	NNS
work_kipbknbmlvekxopym6tsxywxe4	5	7	in	in	IN
work_kipbknbmlvekxopym6tsxywxe4	5	8	animals	animal	NNS
work_kipbknbmlvekxopym6tsxywxe4	5	9	,	,	,
work_kipbknbmlvekxopym6tsxywxe4	5	10	as	as	RB
work_kipbknbmlvekxopym6tsxywxe4	5	11	well	well	RB
work_kipbknbmlvekxopym6tsxywxe4	5	12	as	as	IN
work_kipbknbmlvekxopym6tsxywxe4	5	13	GMP	GMP	NNP
work_kipbknbmlvekxopym6tsxywxe4	5	14	studies	study	NNS
work_kipbknbmlvekxopym6tsxywxe4	5	15	,	,	,
work_kipbknbmlvekxopym6tsxywxe4	5	16	are	be	VBP
work_kipbknbmlvekxopym6tsxywxe4	5	17	necessary	necessary	JJ
work_kipbknbmlvekxopym6tsxywxe4	5	18	before	before	IN
work_kipbknbmlvekxopym6tsxywxe4	5	19	the	the	DT
work_kipbknbmlvekxopym6tsxywxe4	5	20	vaccine	vaccine	NN
work_kipbknbmlvekxopym6tsxywxe4	5	21	enters	enter	VBZ
work_kipbknbmlvekxopym6tsxywxe4	5	22	the	the	DT
work_kipbknbmlvekxopym6tsxywxe4	5	23	clinic	clinic	NN
work_kipbknbmlvekxopym6tsxywxe4	5	24	.	.	.
work_kipbknbmlvekxopym6tsxywxe4	6	1	Castillo	Castillo	NNP
work_kipbknbmlvekxopym6tsxywxe4	6	2	Pharmaceuticals	Pharmaceuticals	NNP
work_kipbknbmlvekxopym6tsxywxe4	6	3	Inc.	Inc.	NNP
work_kipbknbmlvekxopym6tsxywxe4	6	4	’s	’s	POS
work_kipbknbmlvekxopym6tsxywxe4	6	5	SP-304	SP-304	NNP
work_kipbknbmlvekxopym6tsxywxe4	6	6	,	,	,
work_kipbknbmlvekxopym6tsxywxe4	6	7	a	a	DT
work_kipbknbmlvekxopym6tsxywxe4	6	8	GUCY2C	GUCY2C	NNP
work_kipbknbmlvekxopym6tsxywxe4	6	9	agonist	agonist	NN
work_kipbknbmlvekxopym6tsxywxe4	6	10	,	,	,
work_kipbknbmlvekxopym6tsxywxe4	6	11	is	be	VBZ
work_kipbknbmlvekxopym6tsxywxe4	6	12	in	in	IN
work_kipbknbmlvekxopym6tsxywxe4	6	13	Phase	Phase	NNP
work_kipbknbmlvekxopym6tsxywxe4	6	14	I	-PRON-	PRP
work_kipbknbmlvekxopym6tsxywxe4	6	15	testing	test	VBG
work_kipbknbmlvekxopym6tsxywxe4	6	16	to	to	TO
work_kipbknbmlvekxopym6tsxywxe4	6	17	treat	treat	VB
work_kipbknbmlvekxopym6tsxywxe4	6	18	irritable	irritable	JJ
work_kipbknbmlvekxopym6tsxywxe4	6	19	bowel	bowel	NN
work_kipbknbmlvekxopym6tsxywxe4	6	20	syndrome	syndrome	NN
work_kipbknbmlvekxopym6tsxywxe4	6	21	(	(	-LRB-
work_kipbknbmlvekxopym6tsxywxe4	6	22	IBS	IBS	NNP
work_kipbknbmlvekxopym6tsxywxe4	6	23	)	)	-RRB-
work_kipbknbmlvekxopym6tsxywxe4	6	24	.	.	.
work_kipbknbmlvekxopym6tsxywxe4	7	1	Ironwood	Ironwood	NNP
work_kipbknbmlvekxopym6tsxywxe4	7	2	Pharmaceuticals	Pharmaceuticals	NNPS
work_kipbknbmlvekxopym6tsxywxe4	7	3	and	and	CC
work_kipbknbmlvekxopym6tsxywxe4	7	4	Forest	Forest	NNP
work_kipbknbmlvekxopym6tsxywxe4	7	5	Laboratories	Laboratories	NNPS
work_kipbknbmlvekxopym6tsxywxe4	7	6	are	be	VBP
work_kipbknbmlvekxopym6tsxywxe4	7	7	developing	develop	VBG
work_kipbknbmlvekxopym6tsxywxe4	7	8	MD-1100	MD-1100	NNS
work_kipbknbmlvekxopym6tsxywxe4	7	9	,	,	,
work_kipbknbmlvekxopym6tsxywxe4	7	10	a	a	DT
work_kipbknbmlvekxopym6tsxywxe4	7	11	GUCY2C	GUCY2C	NNP
work_kipbknbmlvekxopym6tsxywxe4	7	12	agonist	agonist	NN
work_kipbknbmlvekxopym6tsxywxe4	7	13	that	that	WDT
work_kipbknbmlvekxopym6tsxywxe4	7	14	is	be	VBZ
work_kipbknbmlvekxopym6tsxywxe4	7	15	in	in	IN
work_kipbknbmlvekxopym6tsxywxe4	7	16	Phase	Phase	NNP
work_kipbknbmlvekxopym6tsxywxe4	7	17	II	ii	CD
work_kipbknbmlvekxopym6tsxywxe4	7	18	testing	testing	NN
work_kipbknbmlvekxopym6tsxywxe4	7	19	to	to	TO
work_kipbknbmlvekxopym6tsxywxe4	7	20	treat	treat	VB
work_kipbknbmlvekxopym6tsxywxe4	7	21	constipation	constipation	NN
work_kipbknbmlvekxopym6tsxywxe4	7	22	and	and	CC
work_kipbknbmlvekxopym6tsxywxe4	7	23	IBS	IBS	NNP
work_kipbknbmlvekxopym6tsxywxe4	7	24	.	.	.
work_kipbknbmlvekxopym6tsxywxe4	8	1	Patent	patent	NN
work_kipbknbmlvekxopym6tsxywxe4	8	2	applications	application	NNS
work_kipbknbmlvekxopym6tsxywxe4	8	3	submitted	submit	VBD
work_kipbknbmlvekxopym6tsxywxe4	8	4	;	;	:
work_kipbknbmlvekxopym6tsxywxe4	8	5	Targeted	Targeted	NNP
work_kipbknbmlvekxopym6tsxywxe4	8	6	Diagnostics	Diagnostics	NNPS
work_kipbknbmlvekxopym6tsxywxe4	8	7	&	&	CC
work_kipbknbmlvekxopym6tsxywxe4	8	8	Therapeutics	Therapeutics	NNP
work_kipbknbmlvekxopym6tsxywxe4	8	9	Inc.	Inc.	NNP
work_kipbknbmlvekxopym6tsxywxe4	8	10	has	have	VBZ
work_kipbknbmlvekxopym6tsxywxe4	8	11	exclusive	exclusive	JJ
work_kipbknbmlvekxopym6tsxywxe4	8	12	worldwide	worldwide	JJ
work_kipbknbmlvekxopym6tsxywxe4	8	13	rights	right	NNS
work_kipbknbmlvekxopym6tsxywxe4	8	14	to	to	IN
work_kipbknbmlvekxopym6tsxywxe4	8	15	the	the	DT
work_kipbknbmlvekxopym6tsxywxe4	8	16	GUCY2C	GUCY2C	NNP
work_kipbknbmlvekxopym6tsxywxe4	8	17	cancer	cancer	NN
work_kipbknbmlvekxopym6tsxywxe4	8	18	technology	technology	NN
work_kipbknbmlvekxopym6tsxywxe4	8	19	and	and	CC
work_kipbknbmlvekxopym6tsxywxe4	8	20	has	have	VBZ
work_kipbknbmlvekxopym6tsxywxe4	8	21	sublicensed	sublicense	VBN
work_kipbknbmlvekxopym6tsxywxe4	8	22	most	most	JJS
work_kipbknbmlvekxopym6tsxywxe4	8	23	of	of	IN
work_kipbknbmlvekxopym6tsxywxe4	8	24	the	the	DT
work_kipbknbmlvekxopym6tsxywxe4	8	25	cancer	cancer	NN
work_kipbknbmlvekxopym6tsxywxe4	8	26	applications	application	NNS
work_kipbknbmlvekxopym6tsxywxe4	8	27	to	to	IN
work_kipbknbmlvekxopym6tsxywxe4	8	28	Millennium	Millennium	NNP
work_kipbknbmlvekxopym6tsxywxe4	8	29	Pharmaceuticals	Pharmaceuticals	NNP
work_kipbknbmlvekxopym6tsxywxe4	8	30	Inc.	Inc.	NNP
work_kipbknbmlvekxopym6tsxywxe4	8	31	;	;	:
work_kipbknbmlvekxopym6tsxywxe4	8	32	some	some	DT
work_kipbknbmlvekxopym6tsxywxe4	8	33	of	of	IN
work_kipbknbmlvekxopym6tsxywxe4	8	34	the	the	DT
work_kipbknbmlvekxopym6tsxywxe4	8	35	vaccine	vaccine	NN
work_kipbknbmlvekxopym6tsxywxe4	8	36	applications	application	NNS
work_kipbknbmlvekxopym6tsxywxe4	8	37	available	available	JJ
work_kipbknbmlvekxopym6tsxywxe4	8	38	for	for	IN
work_kipbknbmlvekxopym6tsxywxe4	8	39	sublicensing	sublicense	VBG
work_kipbknbmlvekxopym6tsxywxe4	8	40	Snook	Snook	NNP
work_kipbknbmlvekxopym6tsxywxe4	8	41	,	,	,
work_kipbknbmlvekxopym6tsxywxe4	8	42	A.	A.	NNP
work_kipbknbmlvekxopym6tsxywxe4	8	43	et	et	FW
work_kipbknbmlvekxopym6tsxywxe4	8	44	al	al	NNP
work_kipbknbmlvekxopym6tsxywxe4	8	45	.	.	.
work_kipbknbmlvekxopym6tsxywxe4	9	1	J.	J.	NNP
work_kipbknbmlvekxopym6tsxywxe4	9	2	Natl	Natl	NNP
work_kipbknbmlvekxopym6tsxywxe4	9	3	.	.	.
work_kipbknbmlvekxopym6tsxywxe4	10	1	Cancer	Cancer	NNP
work_kipbknbmlvekxopym6tsxywxe4	10	2	Inst	Inst	NNP
work_kipbknbmlvekxopym6tsxywxe4	10	3	.	.	.
work_kipbknbmlvekxopym6tsxywxe4	11	1	;	;	:
work_kipbknbmlvekxopym6tsxywxe4	11	2	published	publish	VBN
work_kipbknbmlvekxopym6tsxywxe4	11	3	online	online	JJ
work_kipbknbmlvekxopym6tsxywxe4	11	4	June	June	NNP
work_kipbknbmlvekxopym6tsxywxe4	11	5	24	24	CD
work_kipbknbmlvekxopym6tsxywxe4	11	6	,	,	,
work_kipbknbmlvekxopym6tsxywxe4	11	7	2008	2008	CD
work_kipbknbmlvekxopym6tsxywxe4	11	8	;	;	:
work_kipbknbmlvekxopym6tsxywxe4	11	9	doi:10.1093	doi:10.1093	NNP
work_kipbknbmlvekxopym6tsxywxe4	11	10	/	/	SYM
work_kipbknbmlvekxopym6tsxywxe4	11	11	jnci	jnci	NNP
work_kipbknbmlvekxopym6tsxywxe4	11	12	/	/	SYM
work_kipbknbmlvekxopym6tsxywxe4	11	13	djn178	djn178	NNP
work_kipbknbmlvekxopym6tsxywxe4	11	14	Contact	Contact	NNP
work_kipbknbmlvekxopym6tsxywxe4	11	15	:	:	:
work_kipbknbmlvekxopym6tsxywxe4	11	16	Scott	Scott	NNP
work_kipbknbmlvekxopym6tsxywxe4	11	17	A.	A.	NNP
work_kipbknbmlvekxopym6tsxywxe4	11	18	Waldman	Waldman	NNP
work_kipbknbmlvekxopym6tsxywxe4	11	19	,	,	,
work_kipbknbmlvekxopym6tsxywxe4	11	20	Thomas	Thomas	NNP
work_kipbknbmlvekxopym6tsxywxe4	11	21	Jefferson	Jefferson	NNP
work_kipbknbmlvekxopym6tsxywxe4	11	22	University	University	NNP
work_kipbknbmlvekxopym6tsxywxe4	11	23	,	,	,
work_kipbknbmlvekxopym6tsxywxe4	11	24	Philadelphia	Philadelphia	NNP
work_kipbknbmlvekxopym6tsxywxe4	11	25	,	,	,
work_kipbknbmlvekxopym6tsxywxe4	11	26	Pa.	Pennsylvania	NNP
work_kipbknbmlvekxopym6tsxywxe4	11	27	e	e	NN
work_kipbknbmlvekxopym6tsxywxe4	11	28	-	-	NN
work_kipbknbmlvekxopym6tsxywxe4	11	29	mail	mail	NN
work_kipbknbmlvekxopym6tsxywxe4	11	30	:	:	:
work_kipbknbmlvekxopym6tsxywxe4	11	31	scott.waldman@jefferson.edu	scott.waldman@jefferson.edu	ADD
work_kipbknbmlvekxopym6tsxywxe4	11	32	http://www.scibx.com	http://www.scibx.com	ADD
work_kipbknbmlvekxopym6tsxywxe4	11	33	mailto:scott.waldman@jefferson.edu	mailto:scott.waldman@jefferson.edu	NNS
work_kipbknbmlvekxopym6tsxywxe4	11	34	Guanylyl	Guanylyl	NNP
work_kipbknbmlvekxopym6tsxywxe4	11	35	cyclase	cyclase	NN
work_kipbknbmlvekxopym6tsxywxe4	11	36	2C	2c	NN
work_kipbknbmlvekxopym6tsxywxe4	11	37	(	(	-LRB-
work_kipbknbmlvekxopym6tsxywxe4	11	38	heat	heat	NN
work_kipbknbmlvekxopym6tsxywxe4	11	39	-	-	HYPH
work_kipbknbmlvekxopym6tsxywxe4	11	40	stable	stable	JJ
work_kipbknbmlvekxopym6tsxywxe4	11	41	enterotoxin	enterotoxin	NN
work_kipbknbmlvekxopym6tsxywxe4	11	42	receptor	receptor	NN
work_kipbknbmlvekxopym6tsxywxe4	11	43	;	;	:
work_kipbknbmlvekxopym6tsxywxe4	11	44	GUCY2C	gucy2c	LS
work_kipbknbmlvekxopym6tsxywxe4	11	45	)	)	-RRB-
work_kipbknbmlvekxopym6tsxywxe4	11	46	Summary	summary	NN
work_kipbknbmlvekxopym6tsxywxe4	11	47	Licensing	licensing	NN
work_kipbknbmlvekxopym6tsxywxe4	11	48	Status	status	NN
work_kipbknbmlvekxopym6tsxywxe4	11	49	References	reference	NNS